For General Information, page-2999

18/09/23 13:37 Post #: 69900668We
Anp
need to submit the international IP applications on those new applications of ATL1102 as partnership licensing is only going to happen for current IP that ANP has registered (or to a lesser extent, patents in the application process).

Annual report Page 9 shows we have already submitted 3 international patent applications for DMD and muscular dystrophy and other uses: International PCT/AU2018/051353, International PCT/AU2020/050445, and International PCT/AU2022/051129. ATL will submit another International application on combination therapy in DMD in due course based on data in Australian Provisional application 2023900242 on page 10.

ATL1102 invention patents expired in 2019 so anyone*can apply for a methods of use patent using it.

Others cannot use ATL1102 in methods we have already claimed in our international DMD. ,,Anp own ATL1102 for the use in the above methods and are well protected by patent applications and also page 10 commercial exclusivity as we own our package of data generated in mouse, monkeys, and human trials, and the manufacture of ATL1102. https://www.antisense.com.au/wp-content/uploads/2023/08/AT-AR2023_web.pdf*If others do come up with new methods to treat other disease and lodge a method of use patent, they will come to ANP to exclusively license it to Anp thereby blocking others. Alternatively, they could need to buy access to our data package to save time to get into patient studies so ANP will benefit.

Boomy I hope this helps you and others understand that ANP is well protected in every way regarding ATL1102 world wide .